Latest Content

10 of 2215 Shown
  • Interactive Virtual Presentation cme-icon ce-icon

    Current Evidence on Integrase Inhibitors in First-line therapy: Should They Be Your First Choice?

    Joseph J. Eron, Jr., MD, and Daniel Kuritzkes, MD, review the evolving use of INSTIs in patients beginning HIV therapy.
    Faculty: Daniel R. Kuritzkes MD
    Released: 11/20/2014
  • Current Evidence on Integrase Inhibitors in First-line therapy: Should They Be Your First Choice?

    In this downloadable slideset, Joseph J. Eron, Jr., MD, and Daniel Kuritzkes, MD, review key data on the evolving use of INSTIs in patients beginning HIV therapy.
    Date Posted: 11/20/2014
  • Ebola: Jumping on to the Front Lines

    Charles van der Horst MD - 11/18/2014
    How a transformative Skype call led me to leave for Liberia.
  • What the iPrEX Study Taught Me About Adherence Counseling

    Kevin M. O'Hara PA - 10/24/2014 1 comment / Last Comment: 11/7/2014
    iPrEX OLE showed that perfect adherence was not required to attain the benefits of PrEP. How should that influence our approach to adherence counseling for our patients?
  • A Quandary Over Switching: When Patients Resist My Recommendation to Switch

    David A. Wohl MD - 10/15/2014 2 comments / Last Comment: 10/29/2014
    I usually recommend patients who are still receiving lopinavir/ritonavir-based regimens to switch. But how strongly should I urge them to switch when they are reluctant?
  • Learning Module cme-icon

    Highlights of AIDS 2014

    In this Expert Analysis, David A. Cooper, MD, DSc, and Joel E. Gallant, MD, MPH, provide a comprehensive review of the most clinically significant new data from the 2014 International AIDS Conference, along with downloadable slides.
    Faculty: David A. Cooper MD, DSc, Joel E. Gallant MD, MPH
    Released: 10/13/2014
  • Choosing a Single-Tablet Regimen for HIV Patients: What Do the Latest IAS-USA Guidelines Have to Say?

    Renslow Sherer MD - 10/7/2014 3 comments / Last Comment: 10/28/2014
    How I apply recent guidelines in daily practice to offer eligible patients the benefits of single-tablet regimens.
  • To Switch or Not to Switch: Management of First-line Boosted PI Virologic Failure

    W. David Hardy MD - 10/7/2014 2 comments / Last Comment: 11/18/2014
    After a first-line boosted PI regimen fails virologically, when is it OK to stay the course vs making a regimen switch?
  • Deintensification Strategies Using Boosted PIs: Are They Ready for Prime Time?

    Paul E. Sax MD - 10/7/2014 4 comments / Last Comment: 10/18/2014
    Recent studies have highlighted the potential efficacy of 2-drug boosted PI regimens. Are you considering integrating these strategies into your practice?
  • Clinical Focus cme-icon

    The Role of New HCV Agents in Managing HIV/HCV Coinfection

    In this interactive program, Mark S. Sulkowski, MD, discusses the latest expert recommendations and clinical trial data relevant to the treatment of HIV/HCV-coinfected patients.
    Faculty: Mark S. Sulkowski MD
    Released: 10/7/2014
10 of 2215 Shown
Show 10 More
Loading...  
Decision Support
Free
inPractice
Immediate answers to treatment questions
More than just up to date